The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors (NCT05131815) | Clinical Trial Compass
CompletedNot Applicable
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
United States8 participantsStarted 2022-07-25
Plain-language summary
The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors. AYAs who were diagnosed with cancer and have completed cancer treatment will be recruited for this study. This study will enroll 20 participants in total and will last approximately 3 months.
Who can participate
Age range18 Years – 39 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Cancer (all types) diagnosis between the ages of 15-39
* Between the ages of 18-39 during study participation
* At least 3 months post-active treatment completion
* Answers "no" to all questions on the Physical Activity Readiness Questionnaire
* Not currently meeting physical activity guidelines per leisure-time physical activity participation questionnaire
* Access to and ability to use a computer, tablet or phone device with internet access
* Ability to understand and read English
* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study
Exclusion Criteria:
* Hearing loss or vision impairment that would preclude the participant from accessing and using the app (use of hearing aids or visual aids is acceptable) based on self-report
* Currently meeting physical activity guidelines (score of \>23 on Godin-Shephard Leisure-Time Physical Activity Questionnaire)
* Currently pregnant, based on self-report
* Patients with active treatment planned within the next 3 months. (Active treatment includes chemotherapy, biologic therapy, radiation therapy, surgery, and any combination.) Long-term hormonal/biologic treatments are acceptable except for AR-targeted therapies for prostate cancer. Participants with known metastatic disease, grade 3 or higher neuropathy, major surgery within 3 months of baseline visit, pregnancy of childbearing potential will be excluded.